Synapse Biomedical, founded in 2002, commercializes diaphragm pacing systems to treat chronic respiratory insufficiency. Its core technology, the NeuRx DPS, is an FDA-approved implantable neurostimulator that activates the diaphragm muscle, aiming to wean patients off mechanical ventilation. The company serves spinal cord injury and ALS patients, has treated over 2,000 patients, and operates globally. It is a private, commercial-stage company with a focused pipeline in neurostimulation.
Implantable diaphragm pacing system using electrical stimulation of the phrenic nerves to activate the diaphragm muscle, providing ventilatory support and preventing muscle atrophy.
Funding History
5
Total raised:$323M
Follow-on Offering$290MBarclays
Series C$15MUndisclosed
Debt$2.5MUndisclosed
Series B$10MUndisclosed
Opportunities
Expanding adoption of diaphragm pacing as a standard of care for ventilator-dependent spinal cord injury and ALS patients presents a significant growth opportunity.
The TransAeris system opens the large acute care/hospital market for preventing ventilator-induced diaphragm dysfunction in ICU patients.
International market expansion through representatives provides another pathway for growth.
Risk Factors
The company's market is limited to niche neurological patient populations, constraining total addressable market size.
It faces competition from advancing conventional ventilator technology and potential new neuromodulation entrants.
As a small, private firm, it carries execution risks in scaling operations and dependency on a narrow product line.
Competitive Landscape
Synapse competes in the ventilatory support market, primarily against manufacturers of traditional positive-pressure mechanical ventilators (e.g., Philips, Medtronic, ResMed). It holds a first-mover advantage in commercially available diaphragm pacing systems for spinal cord injury. Potential future competitors include other neurostimulation companies developing phrenic nerve stimulators or novel respiratory assist devices.
